Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

	Application Number	PC1/GB2003/001147	
POWER OF ATTORNEY	Filing Date	29 March 2005	
and	First Named Inventor	Jonathan Henry ELLIS	
CORRESPONDENCE ADDRESS	Title	IMMUNOGLOBULINS	
INDICATION FORM	Art Unit		
	Examiner Name		
	Attorney Docket Number	PB60806	
I hereby appoint:  ■ Practitioners associated with the Customer Numbers. 20462  Or  □ Practitioner(s) named below:			
Name		Registration Number	
As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.			
Please recognize or change the correspondence address for the above-identified application to:  The address associated with the above-mentioned Customer Number:  Or  The address associated with Customer Number 20462			
Or □ Firm or Individual Name:	<u></u>		
Address:			
Address:	State	7:	
City:	State:	Zip:	
Country:			
Telephone:	Fax:		
I am the:  Applicant/Inventor: Assignee or record of the entire interest. See 37 Statemenrupger 37 CFR 3.73(b) is enclosed. (Fo			
	or Applicant or Assignee of Ki		
	Telephone: +44 20 8047 4414	2 5 APR 2005	
		-	
Title and Company: Attorney and Authorised Official, Glaxo Group Limited.  NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.			
Submit multiple forms if more than one signature is required, see below*.			
*Total of: forms are submitted.			
Little are submitted.			

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## **ASSIGNMENT**

WHEREAS I/WE, Jonathan Henry ELLIS, Alexandre EON-DUVAL, Volker GERMASCHEWSKI, Christopher PLUMPTON and Michael Robert WEST all of Stevenage, Hertfordshire, United Kingdom AND Alexandre EON-DUVAL and Nicholas Timothy RAPSON both of c/o Stevenage, Hertfordshire, United Kingdom (hereinafter called "the inventor(s)") have invented or discovered "IMMUNOGLOBULINS" (hereinafter called "the invention") for which patent application Numbers 0407193.2 and 0407197.3 were filed on 30 March 2004 and 30 March 2004 respectively in the United Kingdom and for which an international patent application is now being filed designating the United States of America. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

## PCT/GB2005/001147 filed 29 March 2005

WHEREAS the invention, being made in the course of my employment, belongs to my/our employer, namely GLAXOSMITHKLINE SERVICES UNLIMITED a company incorporated in England whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, and

WHEREAS GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from GLAXOSMITHKLINE SERVICES UNLIMITED the whole right, title and interest in and to the invention and the application, and

GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED have authorised and requested my/our making the application, and

WHEREAS GLAXO GROUP LIMITED a company organised and existing under and by virtue of the laws of England and having its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England, is desirous of acquiring from GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED the whole right, title and interest in and to the invention and the application in respect of the United States of America;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by GLAXOSMITHKLINE SERVICES **UNLIMITED** of the invention and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to GLAXOSMITHKLINE SERVICES UNLIMITED. GLAXOSMITHKLINE SERVICES UNLIMITED in turn hereby assigns and transfers to GLAXOSMITHKLINE RESEARCH AND **DEVELOPMENT LIMITED** its whole right, title and interest in and to the invention and the application. GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to GLAXO GROUP LIMITED its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and GLAXOSMITHKLINE GLAXOSMITHKLINE RESEARCH SERVICES UNLIMITED and **DEVELOPMENT LIMITED** hereby authorise and request any patent arising therefrom in the United States of America be issued to GLAXO GROUP LIMITED.

AND GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for

## **ASSIGNMENT**

WHEREAS I/WE, Jonathan Henry ELLIS, Alexandre EON-DUVAL, Volker GERMASCHEWSKI, Christopher PLUMPTON and Michael Robert WEST all of Stevenage, Hertfordshire, United Kingdom AND Alexandre EON-DUVAL and Nicholas Timothy RAPSON both of c/o Stevenage, Hertfordshire, United Kingdom (hereinafter called "the inventor(s)") have invented or discovered "IMMUNOGLOBULINS" (hereinafter called "the invention") for which patent application Numbers 0407193.2 and 0407197.3 were filed on 30 March 2004 and 30 March 2004 respectively in the United Kingdom and for which an international patent application is now being filed designating the United States of America. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

## PCT/GB2005/001147 filed 29 March 2005

WHEREAS the invention, being made in the course of my employment, belongs to my/our employer, namely GLAXOSMITHKLINE SERVICES UNLIMITED a company incorporated in England whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, and

WHEREAS GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from GLAXOSMITHKLINE SERVICES UNLIMITED the whole right, title and interest in and to the invention and the application, and

GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED have authorised and requested my/our making the application, and

WHEREAS GLAXO GROUP LIMITED a company organised and existing under and by virtue of the laws of England and having its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England, is desirous of acquiring from GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED the whole right, title and interest in and to the invention and the application in respect of the United States of America;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by GLAXOSMITHKLINE SERVICES **UNLIMITED** of the invention and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to GLAXOSMITHKLINE SERVICES UNLIMITED. GLAXOSMITHKLINE SERVICES UNLIMITED in turn hereby assigns and transfers to GLAXOSMITHKLINE RESEARCH AND **DEVELOPMENT LIMITED** its whole right, title and interest in and to the invention and the application. GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to GLAXO GROUP LIMITED its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and GLAXOSMITHKLINE and GLAXOSMITHKLINE RESEARCH **SERVICES** UNLIMITED **DEVELOPMENT LIMITED** hereby authorise and request any patent arising therefrom in the United States of America be issued to GLAXO GROUP LIMITED.

AND GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers,

affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **GLAXO GROUP LIMITED**, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IN WITNESS whereof and with effect from 30 March 2004 the inventor(s) and Peter John GIDDINGS as Attorney of both GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED by virtue of Powers of Attorney granted by GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED respectively have hereunto set their respective hands.

SIGNED by Jonathan Henry ELLIS	 Date:
SIGNED by Alexandre EON-DUVAL	 Date: <u>\$\$</u> /04/2005
SIGNED by Volker GERMASCHEWSKI	 Date:
SIGNED by Christopher PLUMPTON	 Date:

PB60806/US

SIGNED by Nicholas Timothy RAPSON	Date:
SIGNED by Michael Robert WEST	- Date:
SIGNED by Peter John GIDDINGS as GLAXOSMITHKLINE SERVICES UNLIMITED RESEARCH AND DEVELOPMENT LIMITED:	
Da	0 9 MAY 2005